Compare Royal Bank of Canada (RY) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Bank of Canada vs Zimmer Biomet Holdings Inc — how do they compare? Royal Bank of Canada trades at $210.44 (market cap $292.92B), while Zimmer Biomet Holdings Inc trades at $97.03 (market cap $18.65B). The key difference: Royal Bank of Canada is far larger — about 15.7× Zimmer Biomet Holdings Inc's market cap, and Royal Bank of Canada pays the higher dividend (2.36%). Which is the better fit depends on your goals.
| RY | ZBH | |
|---|---|---|
Market Cap | $292.92B | $18.65B |
Sector | Financials | Health |
52-Week High | $217.87 | $107.71 |
52-Week Low | $134.80 | $79.58 |
Dividend Yield | 2.36% | 0.98% |
Enterprise Value | — | $25.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Bank of Canada (RY) trades at $211.08, down 0.17% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.84 exceeding expectations. Revenue grew to $66.53B in 2025, and net income margin improved to 31.85%. Analyst consensus is mixed, with 43% buy ratings, while recent news highlights insider selling and institutional adjustments to holdings.
RY presents a solid investment case with robust profitability and consistent earnings outperformance, though valuation ratios like P/E of 19.23 and P/B of 3.17 suggest a premium. Risks include high debt levels and macroeconomic sensitivity, but the bullish technical trend and dividend yield support a cautiously optimistic outlook for long-term investors.
Zimmer Biomet (ZBH) trades at $96.55, down 0.66% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.07, and raised its full-year outlook. Revenue growth remains steady, supported by hips, specialty businesses, and technology, though net income margin has moderated from 2023 peaks. Recent corporate news includes a dividend declaration and expansion of its technology center in India.
The outlook for ZBH is positive, driven by consistent earnings beats and strategic growth initiatives, but investors face risks from margin pressure and increasing debt levels. The stock offers potential upside to the consensus target, supported by institutional accumulation, though competitive and macroeconomic headwinds in the medtech sector warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
